457 related articles for article (PubMed ID: 20551839)
21. Dendritic cells in melanoma immunotherapy.
Faries MB; Czerniecki BJ
Curr Treat Options Oncol; 2005 May; 6(3):175-84. PubMed ID: 15869729
[TBL] [Abstract][Full Text] [Related]
22. Human CD141
Lee YS; O'Brien LJ; Walpole CM; Pearson FE; Leal-Rojas IM; Masterman KA; Atkinson V; Barbour A; Radford KJ
J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33737342
[TBL] [Abstract][Full Text] [Related]
23. From Melanoma Development to RNA-Modified Dendritic Cell Vaccines: Highlighting the Lessons From the Past.
Shadbad MA; Hajiasgharzadeh K; Derakhshani A; Silvestris N; Baghbanzadeh A; Racanelli V; Baradaran B
Front Immunol; 2021; 12():623639. PubMed ID: 33692796
[TBL] [Abstract][Full Text] [Related]
24. Immunotherapy and experimental approaches for metastatic melanoma.
Atkins MB
Hematol Oncol Clin North Am; 1998 Aug; 12(4):877-902, viii. PubMed ID: 9759585
[TBL] [Abstract][Full Text] [Related]
25. Three antigen-loading methods in dendritic cell vaccines for metastatic melanoma.
Geskin LJ; Damiano JJ; Patrone CC; Butterfield LH; Kirkwood JM; Falo LD
Melanoma Res; 2018 Jun; 28(3):211-221. PubMed ID: 29543704
[TBL] [Abstract][Full Text] [Related]
26. Human high molecular weight-melanoma associated antigen mimicry by mouse anti-idiotypic monoclonal antibody MK2-23: modulation of the immunogenicity in patients with malignant melanoma.
Mittelman A; Chen GZ; Wong GY; Liu C; Hirai S; Ferrone S
Clin Cancer Res; 1995 Jul; 1(7):705-13. PubMed ID: 9816036
[TBL] [Abstract][Full Text] [Related]
27. A role of immunotherapy in metastatic malignant melanoma.
Allen T; Gundrajakuppam L
Cent Nerv Syst Agents Med Chem; 2012 Sep; 12(3):182-8. PubMed ID: 22697295
[TBL] [Abstract][Full Text] [Related]
28. Toward prediction of immune mechanisms and design of immunotherapies in melanoma.
Tsoka S; Ainali C; Karagiannis P; Josephs DH; Saul L; Nestle FO; Karagiannis SN
Crit Rev Biomed Eng; 2012; 40(4):279-94. PubMed ID: 23140120
[TBL] [Abstract][Full Text] [Related]
29. Combinations of radiation therapy and immunotherapy for melanoma: a review of clinical outcomes.
Barker CA; Postow MA
Int J Radiat Oncol Biol Phys; 2014 Apr; 88(5):986-97. PubMed ID: 24661650
[TBL] [Abstract][Full Text] [Related]
30. Unveil the mysterious mask of cytokine-based immunotherapy for melanoma.
Xu DH; Zhu Z; Xiao H; Wakefield MR; Bai Q; Nicholl MB; Ding VA; Fang Y
Cancer Lett; 2017 May; 394():43-51. PubMed ID: 28254411
[TBL] [Abstract][Full Text] [Related]
31. Immunotherapy of melanoma.
Parmiani G; Castelli C; Rivoltini L; Casati C; Tully GA; Novellino L; Patuzzo A; Tosi D; Anichini A; Santinami M
Semin Cancer Biol; 2003 Dec; 13(6):391-400. PubMed ID: 15001157
[TBL] [Abstract][Full Text] [Related]
32. Current status of melanoma vaccines.
Kuhn CA; Hanke CW
Dermatol Surg; 1997 Aug; 23(8):649-54; discussion 654-5. PubMed ID: 9256911
[TBL] [Abstract][Full Text] [Related]
33. Immunotherapy for advanced melanoma: Current knowledge and future directions.
Nakamura K; Okuyama R
J Dermatol Sci; 2016 Aug; 83(2):87-94. PubMed ID: 27302423
[TBL] [Abstract][Full Text] [Related]
34. Immunological characteristics correlating with clinical response to immunotherapy in patients with advanced metastatic melanoma.
Marshall JA; Forster TH; Purdie DM; Lanagan CM; O'Connor LE; O'Rourke MG; Johnson MK; See JL; Ellem KA; Martinez NR; López JA; Schmidt CW
Immunol Cell Biol; 2006 Jun; 84(3):295-302. PubMed ID: 16681827
[TBL] [Abstract][Full Text] [Related]
35. Immunotherapy of malignant melanoma.
Kadison AS; Morton DL
Surg Clin North Am; 2003 Apr; 83(2):343-70. PubMed ID: 12744613
[TBL] [Abstract][Full Text] [Related]
36. Treatment approaches for advanced cutaneous melanoma.
Stein JA; Brownell I
J Drugs Dermatol; 2008 Feb; 7(2):175-9. PubMed ID: 18335655
[TBL] [Abstract][Full Text] [Related]
37. Immunotherapy for advanced melanoma.
Fang L; Lonsdorf AS; Hwang ST
J Invest Dermatol; 2008 Nov; 128(11):2596-2605. PubMed ID: 18927541
[TBL] [Abstract][Full Text] [Related]
38. Update on immunotherapy for melanoma.
Ribas A
J Natl Compr Canc Netw; 2006 Aug; 4(7):687-94. PubMed ID: 16884670
[TBL] [Abstract][Full Text] [Related]
39. Melanoma immunotherapy.
Sanlorenzo M; Vujic I; Posch C; Dajee A; Yen A; Kim S; Ashworth M; Rosenblum MD; Algazi A; Osella-Abate S; Quaglino P; Daud A; Ortiz-Urda S
Cancer Biol Ther; 2014 Jun; 15(6):665-74. PubMed ID: 24651672
[TBL] [Abstract][Full Text] [Related]
40. [Future of malignant stage I melanoma. Immunology and immunotherapy].
Nicolas JF; Berthier O; Trillet-Lenoir V; Claudy A; Revillard JP
Ann Dermatol Venereol; 1995; 122(5):324-35. PubMed ID: 8572476
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
